In vitro properties and in vivo behavior of technetium-99m labeled fibrinogens.
Fibrinogen was labeled with Tc-99m by two methods and in vitro stability and the in vivo behavior in mice were studied. The Tc-99m labeling was performed by mixing an unreduced fibrinogen (UnFib) or a reduced fibrinogen (ReFib) with Tc-99m pertechnetate in the presence of stannous chloride. In both of them, chelation with Tc-99m resulted in a single radiochemical product. For the in vitro stability studies, Tc-99m labeled fibrinogen (Tc-99m UnFib) was prepared with UnFib, and transchelation with cysteine solution was easy to produce compared to Tc-99m labeled fibrinogen (Tc-99m ReFib) prepared with ReFib. The radioactivity bound to clottable protein for Tc-99m UnFib and Tc-99m ReFib was about 70% and about 69%, respectively. The in vivo behavior of these labeled fibrinogens was studied, and their efficiencies for imaging an abscess and Ehrlich tumor in mice were determined with a gamma camera. Technetium-99m UnFib underwent a rapid partial exchange of the Tc-99m with compounds of the blood buffer system in vivo, resulting in early biologically active and would be incorporated into the abscess and tumor. The uptake in the abscess increased slightly over time with Tc-99m ReFib, but the abscess to blood and abscess to muscle ratios were 0.09 and 2.6 at 5 hr, respectively. Clearly delineated images of abscess were obtained beginning at about 5 hr after injection. The tumor to blood and tumor to muscle ratios were 0.05 and 1.4 at 5 hr, respectively. The Ehrlich tumor image in mice was slightly visible at 10 hr. The short half-life of Tc-99m was inappropriate for fibrinogen with a low pharmacokinetic value, because it was necessary for imaging of the abscess and tumor to take a long time.
Karube
Y
Y
Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.
Ito
S
S
Katsuno
K
K
Takata
J
J
D000038:Abscess / Q000000981:diagnostic imaging; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000000981:diagnostic imaging; D004355:Drug Stability; D005069:Evaluation Studies as Topic; D005340:Fibrinogen / Q000302:isolation & purification / Q000493:pharmacokinetics; D006207:Half-Life; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D015609:Organotechnetium Compounds / Q000302:isolation & purification / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D014018:Tissue Distribution
D015609:Organotechnetium Compounds; C036459:technetium Tc 99m fibrinogen; D005340:Fibrinogen